Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with early-stage breast cancer still develop recurrent disease, and there is need of additional improvement of systemic therapies. Triple-negative breast cancer (TNBC) comprises approximately 15% to 20% of all breast cancers and usually presents with a more aggressive clinical course and poorer outcomes compared with hormone receptor–positive and human epidermal growth factor receptor 2 (HER2) –positive breast cancer, leaving an unmet need for this patient population.¹ To date, no targeted therapies have been approved for the treatment of early-stage TNBC.

中文翻译：

---

卡培他滨在早期乳腺癌中的作用。

全身性辅助或新辅助化学疗法，生物疗法和激素疗法已改善了早期乳腺癌患者的预后。但是，许多早期乳腺癌患者仍会复发，因此需要进一步改善全身疗法。三阴性乳腺癌（TNBC）约占所有乳腺癌的15％至20％，与荷尔蒙受体阳性和人类表皮生长因子受体2（HER2）阳性乳腺癌相比，通常表现出更具侵略性的临床病程和更差的结果癌症，因此该患者人群的需求尚未得到满足。¹迄今为止，尚未批准针对早期TNBC的靶向疗法。